(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 23.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Foghorn Therapeutics's revenue in 2025 is $24,173,000.On average, 3 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,810,994,087, with the lowest FHTX revenue forecast at $1,683,462,477, and the highest FHTX revenue forecast at $1,940,673,836. On average, 3 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,328,243,303, with the lowest FHTX revenue forecast at $1,902,233,457, and the highest FHTX revenue forecast at $2,821,410,753.
In 2027, FHTX is forecast to generate $2,530,620,592 in revenue, with the lowest revenue forecast at $2,261,198,760 and the highest revenue forecast at $2,821,410,753.